Kishida H, Toyama S, Yanaga T, Suzuki K
Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Jpn Heart J. 1988 Nov;29(6):781-93. doi: 10.1536/ihj.29.781.
The clinical effect of nilvadipine, a new calcium antagonist, was investigated in a single blind trial in 19 patients with variant angina pectoris. The efficacy of the drug was evaluated on the basis of frequency of anginal attacks and Holter electrocardiographic findings during observation periods and during two treatment periods when the drug was given in doses of 4 mg twice a day or 4 mg 3 times a day. The frequency of anginal attacks and the consumption of sublingual nitroglycerin tablets decreased significantly in both treatment periods in comparison with those in the observation period before treatment, but in the observation period after treatment tended to increase in comparison with those during the second treatment period. The frequency and duration of ST-segment elevation and the maximum ST-segment elevation confirmed by Holter electrocardiography also improved significantly in both treatment periods, compared with those in the observation period before treatment. Our findings show that nilvadipine is effective for variant angina pectoris at doses of 4 mg twice a day.
在一项针对19例变异型心绞痛患者的单盲试验中，研究了新型钙拮抗剂尼伐地平的临床疗效。根据观察期以及药物每日两次服用4毫克或每日三次服用4毫克的两个治疗期内的心绞痛发作频率和动态心电图检查结果来评估药物疗效。与治疗前的观察期相比，两个治疗期内心绞痛发作频率和舌下硝酸甘油片的消耗量均显著降低，但与第二个治疗期相比，治疗后的观察期内这些指标有升高趋势。与治疗前的观察期相比，两个治疗期内动态心电图证实的ST段抬高频率和持续时间以及最大ST段抬高也有显著改善。我们的研究结果表明，尼伐地平每日两次服用4毫克对变异型心绞痛有效。
